Medicine & Life Sciences
Cholangiocarcinoma
100%
Survival
71%
Pancreatic Neoplasms
67%
Neoplasms
58%
Therapeutics
45%
Fibroblast Growth Factor Receptors
45%
Adenocarcinoma
41%
Biliary Tract Neoplasms
41%
Hepatocellular Carcinoma
40%
Drug Therapy
40%
Progression-Free Survival
36%
selinexor
30%
gemcitabine
28%
Colorectal Neoplasms
28%
Immunotherapy
26%
Sorafenib
25%
Receptor, Fibroblast Growth Factor, Type 2
25%
Nivolumab
24%
Gallbladder Neoplasms
23%
trifluridine tipiracil
22%
Safety
20%
Clinical Trials
17%
Confidence Intervals
17%
Neoadjuvant Therapy
17%
Cell Nucleus Active Transport
17%
Bevacizumab
16%
Squamous Cell Carcinoma
15%
pembrolizumab
15%
atezolizumab
15%
Circulating Tumor DNA
14%
cabozantinib
13%
lenvatinib
13%
Recurrence
13%
130-nm albumin-bound paclitaxel
13%
Pharmacokinetics
13%
pasireotide
13%
ErbB Receptors
13%
Colonic Neoplasms
12%
Neuroendocrine Tumors
12%
Liver Neoplasms
11%
Biliary Tract
11%
Liver
10%
Elderly
10%
Incidence
10%
Clinical Trials, Phase I
10%
Biomarkers
9%
Irinotecan
9%
durvalumab
9%
Vaccines
9%
ensituximab
9%